- Home
- CNTA vs CPRX Comparison
CNTA vs CPRX Comparison
Compare CNTA & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- CPRX
- Stock Information
- Founded
- CNTA 2020
- CPRX 2002
- Country
- CNTA United Kingdom
- CPRX United States
- Employees
- CNTA N/A
- CPRX N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CNTA Health Care
- CPRX Health Care
- Exchange
- CNTA Nasdaq
- CPRX Nasdaq
- Market Cap
- CNTA 2.3B
- CPRX 2.6B
- IPO Year
- CNTA 2021
- CPRX 2006
- Fundamental
- Price
- CNTA $22.24
- CPRX $20.18
- Analyst Decision
- CNTA Strong Buy
- CPRX Strong Buy
- Analyst Count
- CNTA 11
- CPRX 5
- Target Price
- CNTA $30.60
- CPRX $33.20
- AVG Volume (30 Days)
- CNTA 1.4M
- CPRX 1.5M
- Earning Date
- CNTA 11-11-2025
- CPRX 11-05-2025
- Dividend Yield
- CNTA N/A
- CPRX N/A
- EPS Growth
- CNTA N/A
- CPRX 183.96
- EPS
- CNTA N/A
- CPRX 1.65
- Revenue
- CNTA $15,000,000.00
- CPRX $558,499,000.00
- Revenue This Year
- CNTA N/A
- CPRX $16.51
- Revenue Next Year
- CNTA N/A
- CPRX $9.58
- P/E Ratio
- CNTA N/A
- CPRX $12.13
- Revenue Growth
- CNTA 118.88
- CPRX 28.55
- 52 Week Low
- CNTA $9.60
- CPRX $19.15
- 52 Week High
- CNTA $23.24
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- CNTA 68.78
- CPRX 48.24
- Support Level
- CNTA $20.94
- CPRX $19.66
- Resistance Level
- CNTA $23.24
- CPRX $20.52
- Average True Range (ATR)
- CNTA 1.33
- CPRX 0.66
- MACD
- CNTA 0.42
- CPRX 0.04
- Stochastic Oscillator
- CNTA 84.93
- CPRX 49.50
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).